Drug intelligence / Profile preview

MC1

Development stage: Preclinical
Modality: Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

MC1 is a small molecule photosensitizer that selectively targets the RNA G-quadruplex (RG4) structure located in the 5'-untranslated region (5'-UTR) of KRAS mRNA. Developed as a more selective and safer alternative to the ligand MBD, MC1 facilitates photodynamic therapy (PDT) by inducing KRAS RG4 breakage, depleting glutathione (GSH), and oxidizing NADH upon light activation. These actions trigger ferroptosis in cancer cells, particularly in cisplatin-resistant non-small cell lung cancer (NSCLC). Additionally, MC1 serves as a fluorescent probe for the detection and characterization of KRAS RG4.

Targets

KRAS rG4 (KRAS RNA G-quadruplex)Neuroblastoma RAS viral oncogene homolog mRNA G-quadruplex

Beyond the preview

Go deeper on MC1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MC1.

Explore the full profile